Effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axial spondyloarthritis using HR-pQCT.

ABSTRACT: Participants with active AxSpA beginning secukinumab with moderate disease activity had improvements in symptoms, but no substantial change in BMD and microarchitecture. Larger, longer-term controlled studies are needed to assess the impact of IL-17 blockade on skeletal health.

Background

Axial Spondyloarthritis (AxSpA) is linked to poor skeletal health, but whether IL-17 blockade, effective for symptom improvement, improves skeletal health is unknown. We investigated the impact of secukinumab on skeletal features.

Methods

We prospectively enrolled AxSpA patients beginning therapy with secukinumab and followed them for 24 months. Clinical assessments, serum bone turnover markers, and cervical and lumbar spine radiographs were obtained. Areal BMD (aBMD) and trabecular bone sco

SUBMITTER: Heiting C 

PROVIDER: S-EPMC12145278 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature